Profile picture

Professor Young-Hoon Jeong

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong (Korea (Republic of))
Membership: FESC Member
Follow
Biography
Dr. Young-Hoon Jeong is a distinguished cardiologist and professor affiliated with Chung-Ang University Gwang-Myeong Hospital and works as a director in CAU Thrombosis and Biomarker Center in Gwang-Myeong, South Korea. He earned his MD and PhD degrees and has been recognized as a Fellow of both the American Heart Association (FAHA) and the European Society of Cardiology (FESC).​ Throughout his career, Dr. Jeong has contributed extensively to the field of antithrombotic therapy, particularly concerning its application in East Asian patients with acute coronary syndrome or those undergoing percutaneous coronary intervention. His research emphasizes the importance of considering racial differences in drug metabolism and response to optimize treatment outcomes.
Logo ESC

Contributor content

Clinical significance of time-varying on-treatment platelet reactivity after percutaneous coronary intervention
Presentation
Clinical significance of time-varying on-treatment platelet reactivity after percutaneous coronary intervention
Relationship between serial c-reactive protein levels and cardiovascular events in East asian patients treated with percutaneous coronary intervention
Presentation
Relationship between serial c-reactive protein levels and cardiovascular events in East asian patients treated with percutaneous coronary intervention
Influence of amlodipine on antiplatelet effect of clopidogrel in patients treated with percutaneous coronary intervention: result of the randomized, prospective, two-period, crossover, ACCEL-CCB trial
Presentation
Influence of amlodipine on antiplatelet effect of clopidogrel in patients treated with percutaneous coronary intervention: result of the randomized, prospective, two-period, crossover, ACCEL-CCB trial
A randomised, double-blind, placebo controlled trial to evaluate the effect of adjunctive cilostazol on endothelial progenitor cell mobilization in AMI patients: the result of the ACCEL-EPISODE trial
Presentation
A randomised, double-blind, placebo controlled trial to evaluate the effect of adjunctive cilostazol on endothelial progenitor cell mobilization in AMI patients: the result of the ACCEL-EPISODE trial

ESC 365 is supported by